Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock.
Evolus, Inc. commercializes cash-pay medical aesthetic products for the global performance beauty market. Its portfolio centers on Jeuveau® (prabotulinumtoxinA-xvfs), known as Nuceiva® outside the United States, and injectable hyaluronic acid gel collections marketed under the Evolysse® and Estyme® brands.
Recurring Evolus news includes quarterly financial results, revenue outlooks, product and market expansion for injectable aesthetics, CE Mark certification for HA gel collections, national-account and customer engagement updates, healthcare conference participation, and equity compensation grants under Nasdaq inducement rules. Company updates also discuss operations across the United States, Canada, Europe, and Australia.
Evolus (NASDAQ: EOLS) reported inducement grants made in March 2026 under its 2023 Inducement Incentive Plan. The company granted an aggregate of 85,516 RSUs and 8,635 stock options to 10 newly hired non-executive employees, approved by the compensation committee.
The awards vest 25% on each annual anniversary beginning at the vesting commencement date. Options’ exercise price equals the closing price on the last business day prior to each grant. Awards are subject to plan and grant agreement terms, including continuous employment requirements on vesting dates.
Evolus (NASDAQ: EOLS) reported Q4 2025 revenue of $90.3M and full‑year 2025 revenue of $297.2M, representing 14% and 12% growth respectively, its sixth consecutive year of double‑digit growth. The company achieved GAAP operating income of $4.2M in Q4 and ended 2025 with $53.8M cash.
Management provided 2026 guidance of $327M–$337M revenue (10%–13% growth), non‑GAAP operating expense of $210M–$216M (0%–3% growth), and expects a low‑ to mid‑single digit adjusted EBITDA margin in 2026, while forecasting $450M–$500M revenue and 13%–15% adjusted EBITDA margins in 2028.
Evolus (NASDAQ: EOLS) said its management team will participate in a fireside chat and investor meetings at the Leerink Partners Global Healthcare Conference in Miami on Wednesday, March 11, 2026 at 11:20 AM ET. The webcast will be available on the company Investor Relations page and a replay will be posted for 90 days.
Evolus (NASDAQ: EOLS) will report fourth quarter and full-year 2025 financial results on Tuesday, March 3, 2026 after U.S. market close. Management will host a conference call and live webcast at 4:30 p.m. ET the same day, followed by Q&A.
Dial-in numbers, webcast links, telephonic replay details, and an archived webcast will be available on the company's Investor Relations website.
Evolus (NASDAQ: EOLS) announced inducement equity grants to 36 newly hired non-executive employees comprising 153,218 restricted stock units and 34,952 stock options granted between December 7, 2025 and February 7, 2026.
The awards were approved under the 2023 Inducement Incentive Plan, vest 25% annually, and options carry an exercise price equal to the closing price on the last business day before each grant date.
Evolus (NASDAQ: EOLS) reported preliminary unaudited net revenue of $88.6M–$90.6M for Q4 2025 (up 12%–15% YoY) and $295.5M–$297.5M for full-year 2025 (up 11%–12% YoY). The company reaffirmed Q4 2025 non-GAAP operating income of $5M–$7M and provided 2026 net revenue guidance of $327M–$337M (11%–13% growth vs. preliminary 2025). Evolysse and Estyme injectable HA gels are expected to contribute 10%–12% of 2026 revenue. Cash and equivalents were $53M as of Dec 31, 2025. Long-term outlook updated to $450M–$500M revenue for 2028 with 13%–15% non-GAAP operating margins.
Evolus (NASDAQ: EOLS) announced inducement equity grants approved under the Evolus 2023 Inducement Incentive Plan with a grant and vesting commencement date of November 7, 2025.
The company granted non-qualified stock options to purchase an aggregate of 17,871 shares and 45,063 restricted stock units (RSUs) to 13 newly hired non-executive employees. The stock options carry an exercise price of $6.56 (closing price on November 7, 2025), a 10-year term, and vest over 4 years with 25% vesting each annual anniversary. RSUs vest 25% on each annual anniversary.
All awards are subject to the plan and to individual award agreements, including continuous employment vesting conditions, and were approved as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
Evolus (NASDAQ: EOLS) reported Q3 2025 total net revenue of $69.0 million, up 13% year-over-year, including $63.2 million in global Jeuveau revenue and $5.7 million from Evolysse. Gross margin was 66.5% (adjusted 67.6%). GAAP operating loss narrowed to $11.5 million; non-GAAP loss from operations was $3.1 million. Cash and cash equivalents were $43.5 million on September 30, 2025 after proactive inventory purchases. The company reaffirmed 2025 revenue guidance of $295–$305 million, non-GAAP OpEx of $208–$213 million, and now expects positive non-GAAP operating income of $5–$7 million in Q4 2025.
Evolus (NASDAQ: EOLS) said members of its management team will participate in a fireside chat and investor meetings at the 2025 Stifel Healthcare Conference. The fireside chat is scheduled for Tuesday, November 11, 2025 at 11:20 AM ET. Investors can access the live webcast on Evolus' Investor Relations page, and a replay will be available for 90 days after the presentation date.
This notice provides event timing, access details, and replay availability for shareholders and market observers.
Evolus (NASDAQ: EOLS) will report its third quarter 2025 financial results on Wednesday, November 5, 2025 after U.S. markets close. Management will host a conference call and live webcast at 4:30 p.m. ET the same day, followed by a question-and-answer session.
Investors can join the call by dialing (877) 407-6184 (U.S.) or (201) 389-0877 (international), or listen via the live webcast on the Evolus Investor Relations page. A telephonic replay will be available at (877) 660-6853 (U.S.) or (201) 612-7415 (international) using conference number 13756397. An archived webcast will be posted at www.evolus.com.